- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02147886
Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease
A Single-Center, Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Patients With Machado-Joseph Disease
- This is an exploratory, randomized, parallel-group, dose escalation and dose-controlled study without a placebo arm.
- Eligible patients will be randomized in a 1:1 ratio (double-blind) to receive Cabaletta in 2 doses, once weekly for 22 weeks (total of 24 weeks of treatment).
Study Overview
Status
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Kfar Saba, Israel
- Meir Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women, 18 - 75 years
- Clinically diagnosed as Machado-Joseph disease/Spinocerebellar ataxia 3 confirmed by genetic testing
- With disease stage 2 or less
- Stable doses of all medications for 30 days prior to study entry and for the duration of the study.
- Body Mass Index (BMI) ≤32 kg/m2.
- Ability to ambulate with or without assistance
Exclusion Criteria:
- Diabetes mellitus type 1 or 2
- Other major diseases
- Uncontrolled heart disease, chronic heart failure (CHF).
- Other neurological diseases.
- Ataxia derived from any other cause than genetically-confirmed spinocerebellar ataxia
- Presence of psychosis, bipolar disorder, untreated depression
- History of malignancy (except non-invasive skin malignancy).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cabaletta 15gr
|
Cabaletta for IV infusion once weekly
|
Experimental: Cabaletta 30gr
|
Cabaletta for IV infusion once weekly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: 28 weeks
|
Safety will be evaluated on the basis of the following assessments: Adverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations |
28 weeks
|
Physical examination
Time Frame: 28 weeks
|
Safety will be evaluated on the basis of the following assessments: Adverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations |
28 weeks
|
Vital signs
Time Frame: 28weeks
|
Safety will be evaluated on the basis of the following assessments: Adverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations |
28weeks
|
12-lead ECG
Time Frame: 28weeks
|
Safety will be evaluated on the basis of the following assessments: Adverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations |
28weeks
|
Safety laboratory tests
Time Frame: 28weeks
|
Safety will be evaluated on the basis of the following assessments: Adverse events , physical examination, 12-lead ECG, vital signs, safety laboratory evaluations |
28weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease markers
Time Frame: 27 weeks
|
Changes in disease markers will be assessed based on the following assessments: Scale for the Assessment and Rating of Ataxia (SARA); Neurological Examination Score for Spinocerebellar Ataxia (NESSCA); Change in BMI - screening, spinocerebellar Ataxia Functional Tests; quality of life |
27 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biochemical marker
Time Frame: 27 weeks
|
Assessment of disease biochemical marker neuron specific enolase (NSE) and protein S 100 B (S100B)
|
27 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Carlos Gordon, Prof., Meir Medical Center Kfar Saba Israel
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Dyskinesias
- Spinal Cord Diseases
- Heredodegenerative Disorders, Nervous System
- Cerebellar Diseases
- Ataxia
- Cerebellar Ataxia
- Spinocerebellar Ataxias
- Spinocerebellar Degenerations
- Machado-Joseph Disease
Other Study ID Numbers
- BB-MJD-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Machado-Joseph Disease / Spinocerebellar Ataxia 3
-
Hospital de Clinicas de Porto AlegreCompletedSpinocerebellar Ataxia Type 3 | Machado Joseph DiseaseBrazil
-
National University of MalaysiaRadboud University Medical CenterRecruiting
-
University of MichiganNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedSpinocerebellar Ataxia Type 3United States
-
BiogenTerminatedSpinocerebellar Ataxia Type 3United States, Netherlands, Israel, Portugal, United Kingdom, Germany
-
University of FloridaAcorda TherapeuticsCompletedSpinocerebellar Ataxias Type 1 | Spinocerebellar Ataxias Type 2 | Spinocerebellar Ataxias Type 3 | Spinocerebellar Ataxias Type 6United States
-
University of FloridaUniversity of California, Los Angeles; National Ataxia FoundationRecruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6United States
-
Hospital de Clinicas de Porto AlegreUnknownNatural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD (BIGPRO)Spinocerebellar Ataxia Type 3 | Machado-Joseph DiseaseBrazil
-
National University of MalaysiaCompletedSpinocerebellar Ataxia 3Malaysia
-
Sclnow Biotechnology Co., Ltd.Not yet recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6
-
University of California, Los AngelesActive, not recruitingSpinocerebellar Ataxias | Spinocerebellar Ataxia 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | MSA-CUnited States
Clinical Trials on Cabaletta for IV infusion once weekly during 24 weeks
-
Eunice Kennedy Shriver National Institute of Child...National Institute on Aging (NIA)Completed
-
Biomedical Development CorporationNational Heart, Lung, and Blood Institute (NHLBI); University of KentuckyUnknownGingivitis | Investigation of Biological Markers of InflammationUnited States
-
Intermountain Health Care, Inc.Intermountain Research and Medical FoundationCompleted
-
Hospital de Clinicas de Porto AlegreUnknownHeart Failure | AnemiaBrazil
-
Alexandria UniversityActive, not recruitingChronic Migraine, HeadacheEgypt
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)RecruitingMenopause | Irritable MoodUnited States
-
Cancer Trials IrelandRecruitingHER2-positive Breast CancerIreland
-
Organon and CoCompleted
-
University of Alabama at BirminghamCompletedVitamin D Deficiency | Type 2 DiabetesUnited States
-
Nationwide Children's HospitalOhio State UniversityUnknownVitamin D Deficiency | AsthmaUnited States